Slide 1: Scientific Congress Presentation Utilization Guidelines
Scientific Congress Presentation Utilization Guidelines Use Case PPT slides PDF file Notes These slides are intended for presentation = ae a purposes only — please do not distribute. For Provision to external physicians oy z special permission to distribute, please fill out the request form Eire (ye
Slide 2: Key baseline disease characteristics in nAMD are not linked to treatment interval extension of aflibercept 8 mg
Key baseline disease characteristics in nAMD are not linked to treatment interval extension of aflibercept 8 mg: A post-hoc 96-week PULSAR analysis Justus G. Garweg,' Paolo Lanzetta,? Varun Chaudhary,’ Sergio Leal,* Tobias Machewitz,> Xin Zhang,‘ on behalf of the PULSAR study investigators 1§wiss Ey
Slide 3: PULSAR: Multicenter, randomized, double-masked study
PULSAR: Multicenter, randomized, double-masked study Patients with treatment-naive nAMD, randomized at baseline 7 v + 298 8q12 8q16 Aflibercept 2 mg every 8 weeks Aflibercept 8 mg every 12 weeks Aflibercept 8 mg every 16 weeks after 3 initial monthly injections after 3 initial monthly injections aft
Slide 4: Baseline demographics and study eye characteristics
Baseline demographics and study eye characteristics Randomized, n 336 335 338 673 1009 Age, years 74.7 (7.9) 74.5 (8.4) Female, % 54.3 54.5 Race, % Asian 22.1 23.2 Black or African American 0.6 0.4 White 76.4 75.8 Not reported Ul 0.6 ; k 0.5 Hispanic or Latino, % 2.1 2.8 Hypertension, % 66.3 BCVA, E
Slide 5: Rationale and objectives of this analysis
Last assigned treatment intervals at Week 96 and objectives of this analysis 8q16 All patients receiving 8 mg (n=292) (n=583) Purpose of this post hoc analysis was to evaluate baseline characteristics in patients treated with aflibercept 8 mg in groups defined by treatment intervals in two different
Slide 6: Understanding treatment interval groupings through Week 96
Understanding treatment interval groupings through Week 96 en Treatment interval Treatment interval grouping Randomized Mos Mqi2 Magic Mi q20 Ml q24 Treatment interval Last assigned treatment group through Week 96 treatment interval 8q12 8q16 8q16 8q12 8q16 8q12 8q16 8q12 D1 Ws W16 W24 W32 W40 W48|
Slide 7: BCVA according to dosing through Week 96
Baseline BCVA according to dosing through Week 96 nAMD | Patients whose treatment intervals were shortened to g8 at any point a o | Patients whose treatment intervals were maintained at q12 throughout the study? | Patients whose treatment intervals were maintained at q16 throughout the study b a Pat
Slide 8: CRT according to dosing through Week 96
Baseline CRT according to oS dosing through Week 96 AMD Patients whose treatment intervals were shortened to g8 at any point Patients whose treatment intervals were maintained at q12 throughout the study? £ o ro} Patients whose treatment intervals were maintained at q16 throughout the study Patients
Slide 9: CNV lesion size according to dosing through Week 96
Baseline CNV lesion size according to dosing through Week 96 nAMD a | Patients whose treatment intervals were shortened to g8 at any point | Patients whose treatment intervals were maintained at q12 throughout the study? o | Patients whose treatment intervals were maintained at q16 throughout the st
Slide 10: BCVA according to last assigned treatment intervals at Week 96
Baseline BCVA according to last assigned treatment intervals at Week 96 Last assigned treatment interval Mos Mai2 Mie MM q20 MM q24 80 QD o QD Ss) (ETDRS letters) os fo) (ETDRS letters) aN Oo N i=} N Ss) $ Oo a o & oO 7) o a < g o = Mean baseline BCVA n=67 8q12 (n=291) n=74 8q16 (n=292) For patients
Slide 11: CRT according to last assigned treatment intervals at Week 96
Baseline CRT according to last assigned treatment intervals at Week 96 Last assigned treatment interval Mos Mai2 Mqi¢ Mq2o Mi 24 600 S fo} fo} = = a oe (6) o £ o o a a iS oy iy = Mean baseline CRT (ym) n=67 n=74 8q12 8q16 (n=291) (n=291) For patients receiving aflibercept 8 mg, minor numerical diffe
Slide 12: CNV lesion size according to last assigned treatment intervals at Week 96
Baseline CNV lesion size according to last assigned treatment intervals at Week 96 Last assigned treatment interval Mos Mai2 Mate M20 Mi q24 a a S S a a Mean baseline CNV lesion area (mm? o © a E — oO ® oO c Ss Y 8 > Zz (3) oO £ oO no oO pel < oO ®D s n=67 n=74 8q12 8q16 (n=291) (n=292) For patients
Slide 13: Conclusions
Conclusions ulsar nAMD At Week 96, 71% of patients receiving aflibercept 8 mg had 2q16 treatment intervals and >27% had q24 treatment intervals This post-hoc analysis of PULSAR showed minor numerical differences in baseline BCVA, CRT, and CNV size across groups of patients defined by dosing interval
Slide 14: Thank you!
nAMD Thank you! • The PULSAR study (NCT04423718) was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation • Medica